SCHEMBL5764207

SCHEMBL5764207

CCC(CC)(C(=O)OC)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.46
CES2 O00748 1/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 1/20 0.42
GPR35 Q9HC97 2/20 0.41
POLB P06746 1/20 0.40
LMNA P02545 1/20 0.39
CFTR P13569 1/20 0.38
ACP1 P24666 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
P2RX1 P51575 1/20 0.38
TMPRSS4 Q9NRS4 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14372751 0.84 GPR35 (0.46) NOTUMCES2ALDH1A1MAPTGPR35
SCHEMBL5767698 0.79 CES2 (0.47) NOTUMCES2ALDH1A1MAPTGPR35
SCHEMBL25175839 0.76 NOTUM (0.44) NOTUMALDH1A1MAPTGPR35POLB
SCHEMBL4030734 0.76 CES2 (0.47) NOTUMCES2ALDH1A1MAPTGPR35
SCHEMBL16183043 0.74 POLB (0.42) ALDH1A1MAPTPOLBLMNASMN1; SMN2
SCHEMBL25167682 0.72 ALOX5 (0.36)
SCHEMBL22838091 0.71 ALDH1A1 (0.43) ALDH1A1MAPTPOLBLMNATSHR
SCHEMBL8785618 0.71 KCNN4 (0.43) ALDH1A1POLBLMNACYP1A2
SCHEMBL25167681 0.70 NOTUM (0.41) NOTUMCES2ALDH1A1MAPTGPR35
SCHEMBL3169019 0.70 MAPT (0.54) CES2ALDH1A1MAPTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1286967-B1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME (GB) 2006-09-27 EP disclosed
US-7105507-B2 Cyclohexane derivatives and their use as therapeutic agents MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20030236250-A1 Cyclohexane derivatives and their use as therapeutic agents MERCK SHARP & DOHME LTD. (GB) 2003-12-25 US disclosed
EP-1286967-A1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2003-03-05 EP disclosed
WO-2001087838-A1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236250-A1 Cyclohexane derivatives and their use as therapeutic agents CNR2, CNR1, HTR1A NOTUM 3450/4885CES2 811/4885ALDH1A1 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.